Physician profile
Russell B Stapleton
NPI 1265498976
$8,738.06
in general payments reported to CMS, 2019-2025
41 companies · $2,079 in 2025
The $2,079 reported for 2025 was more than what 86% of Nuclear Cardiology providers received nationally (typical 2025 total: $434).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $482 · 2020: $204 · 2021: $687 · 2022: $1,504 · 2023: $1,852 · 2024: $1,930 · 2025: $2,079.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,841 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,841.41 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $918.10 | 2019-2025 | Mitraclip, Navitor, Triclip |
| Novartis Pharmaceuticals Corporation | $807.65 | 2019-2025 | |
| Medtronic, INC. | $703.18 | 2022-2025 | Onyx Frontier |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $677.08 | 2019-2025 | Lifevest |
| Pfizer INC. | $671.16 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $539.52 | 2021-2025 | Verquvo, Capvaxive |
| Cvrx, INC. | $465.18 | 2021-2024 | Barostim Neo System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $342.54 | 2020-2025 | Jardiance |
| Astrazeneca Pharmaceuticals Lp | $342.26 | 2021-2025 | Lokelma, Farxiga, Wainua |
| Boston Scientific Corporation | $335.40 | 2022-2023 | Watchman Access System |
| E.R. Squibb & Sons, L.L.C. | $311.26 | 2020-2025 | Camzyos, Eliquis |
| Esperion Therapeutics, INC. | $275.07 | 2023-2025 | Nexletol |
| Amgen INC. | $247.96 | 2019-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $211.25 | 2019-2023 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $192.79 | 2021-2024 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cardiovascular Systems INC. | $192.33 | 2019-2022 | |
| Edwards Lifesciences Corporation | $187.36 | 2022-2024 | Sapien 3 Ultra Resilia |
| United Therapeutics Corporation | $145.52 | 2025 | Tyvaso |
| Siemens Medical Solutions USA, INC. | $124.99 | 2023 | |
| Abiomed | $108.24 | 2019-2025 | |
| Acist Medical Systems, INC. | $100.33 | 2020-2021 | |
| Medtronic Vascular, INC. | $99.08 | 2019 | |
| Irhythm Technologies, INC. | $85.17 | 2023-2024 | Zio Xt Patch, Zio Monitor |
| Scpharmaceuticals INC. | $70.95 | 2025 | |
| Sanofi-Aventis U.S. LLC | $70.27 | 2019-2024 | |
| Lexicon Pharmaceuticals, INC. | $53.71 | 2023-2024 | Inpefa |
| Actelion Pharmaceuticals US, INC. | $52.01 | 2024-2025 | Uptravi, Opsumit, Opsynvi |
| Alnylam Pharmaceuticals INC. | $50.14 | 2021-2025 | Amvuttra |
| Novo Nordisk INC | $44.14 | 2021-2023 | Rybelsus, Ozempic |
| Opsens INC. | $39.99 | 2019 | |
| Shockwave Medical, INC | $39.28 | 2021-2022 | |
| Amarin Pharma, INC. | $38.14 | 2019-2023 | |
| Philips North America LLC | $36.94 | 2025 | Extended Holter |
| Kestra Medical Technology Services, INC. | $31.26 | 2025 | Assure Wcd |
| Kiniksa Pharmaceuticals International, Plc | $22.33 | 2024 | Arcalyst |
| Penumbra, INC. | $19.72 | 2020-2021 | |
| Zoll Circulation INC | $18.99 | 2021 | |
| Impulse Dynamics (USA) INC. | $18.40 | 2022 | |
| Bridgebio Pharma, INC. | $17.73 | 2025 | Attruby |
| Cook Medical LLC | $15.98 | 2019 | |
| Baxter Healthcare | $14.66 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Russell Stapleton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.